Tamalika Chakraborty

Tamalika Chakraborty

Auto-generated profile, based on publicly available information

Tamalika Chakraborty

Department of Biotechnology, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Rd, Sahid Colony, Panihati, Kolkata, West Bengal-700114, India

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Pharmacological Research - Modern Chinese Medicine
Verified
Journal Article
Open access
SBSobhanjan Bhunia
Sobhanjan Bhunia
SMSonia Mallick
Sonia Mallick
AMAsif Iqbal Mondal
Asif Iqbal Mondal
ASArkaprava Saha
Arkaprava Saha
PRPriyanka Ray
Priyanka Ray
TCTamalika Chakraborty
Tamalika Chakraborty

13 February 2023 in International Journal of Life Science and Pharma Research
Verified
Journal Article
Open access
PKPunam Kumari
Punam Kumari
TCTamalika Chakraborty
Tamalika Chakraborty
SGSutripto Ghosh
Sutripto Ghosh
One of the most significant issues faced by humanity today is antibiotic resistance. Drugs are used in such vast amounts for human health, aquatic life, and agricultural animals that harmful bacteria have developed antibiotic resistance to various antibiotics. Further, the usage of antibiotics is increasing because of situations such as increased infections and chronic diseases that need antimicrobial treatment. Since antimicrobial resistance is rising, it is necessary to take action to help reduce and eliminate infectious diseases and ensure animal and human health. Because of this, many attempts are being made to tackle multi-drugresistant bacteria. Among the many advanced techniques that are occurring, the use of phage therapy is one such emerging procedure. The main aim of this prospective review is to identify the various new phage formulations available as a potential therapeutic intervention to combat multidrug resistance among bacteria and the objective is to identify the various reasons associated with the induction of the phenomenon of "multidrug resistance" among different bacteria, focusing on the use of phage therapy, its advantages as well as disadvantages over antibiotics as a possible therapeutic intervention. Various phage formulations, such as phage cocktails with antibiotics, nanoparticles, phage-delivering hydrogels, and many more, are emerging formulations that have successful results in fighting against multi-drug-resistant bacteria. Commercial phage solutions have helped combat antimicrobial resistance in poultry and livestock farms, improving everyone's health worldwide. As a result, this study shall serve as a source of information and understanding of the concerns mentioned above for the entirety of society and every human community.

15 April 2025 in Indian Journal of Clinical Anaesthesia
Verified
Journal Article
Open access
PDF file
ABAshni Bhandari
Ashni Bhandari
KBKrishna Prasanth Baalann
Krishna Prasanth Baalann
ASAjay Chandrasekar V S
Ajay Chandrasekar V S
MKManikandan Kathirvel
Manikandan Kathirvel
TCTamalika Chakraborty
Tamalika Chakraborty
SPS Parthasarathy
S Parthasarathy
AI innovations in anaesthesia: A systematic review of clinical application - IJCA- Print ISSN No: - 2394-4781 Online ISSN No:- 2394-4994 Article DOI No:- 10.18231/j.ijca.2025.032, Indian Journal of Clinical Anaesthesia-Indian J Clin Anaesth

1 May 2024 in European Journal of Theoretical and Applied Sciences
Verified
Journal Article
Open access
PDF file
BDBishal Das
Bishal Das
SSSayanee Sarkar
Sayanee Sarkar
SPSourav Paul
Sourav Paul
AZAyesha Zafar
Ayesha Zafar
DBDeepika Biswas
Deepika Biswas
TCTamalika Chakraborty
Tamalika Chakraborty
The cosmetic industry is a significant contributor to environmental pollution, releasing a wide array of emerging pollutants (EPs) into aquatic ecosystems through its effluents. These EPs, including microplastics, synthetic fragrances, UV filters, and preservatives, originate from various cosmetic products and have been increasingly detected in surface water, municipal wastewater, groundwater, and even drinking water sources. The presence of EPs in these environments poses significant risks to both ecological integrity and human health, necessitating urgent mitigation efforts. This review critically evaluates existing mitigation strategies aimed at reducing the environmental impact of EPs from cosmetic industry effluents. It examines the multifaceted nature of the issue, highlighting the need for comprehensive approaches that encompass regulatory, technological, and collaborative efforts. Regulatory measures are essential for setting standards and enforcing compliance to limit the discharge of harmful chemicals into water bodies. However, technological advancements are equally crucial, with the adoption of advanced treatment processes such as advanced oxidation processes, membrane filtration, adsorption, and biodegradation, offering effective means of removing EPs from effluents. Moreover, raising public awareness about the environmental impact of cosmetic industry effluents is paramount to driving collective action and encouraging consumer demand for eco-friendly products. By implementing and continually refining these mitigation strategies, stakeholders can work towards safeguarding ecosystems and promoting a more sustainable future for generations to come. This comprehensive review provides valuable insights for researchers, policymakers, industry stakeholders, and consumers alike, emphasizing the importance of concerted efforts to address the challenge of emerging pollutants from cosmetic industry effluents.

31 October 2025 in Journal of Applied Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
TCTamalika Chakraborty
Tamalika Chakraborty
SBSobhanjan Bhunia
Sobhanjan Bhunia
SCSumana Chatterjee
Sumana Chatterjee
Background: Antimicrobial resistance (AMR) is a primary global health concern, exacerbated by the ability of drug-resistant pathogens to form biofilms. These biofilms, which harbor microbial communities embedded in an extracellular polymeric matrix (EPS), enhance antibiotic resistance and immune responses, leading to persistent infections. Heterocyclic compounds have shown significant potential in combating biofilm-associated infections due to their structural diversity and mechanisms of action. Methodology: This review systematically examines the antibiofilm potential of various heterocyclic scaffolds, including imidazoles, pyrazoles, indoles, quinolines, coumarins, and select six-membered heterocycles (pyridine, morpholine, piperazine). Studies were analyzed based on their mechanisms of action, structure-activity relationships (SAR), and synergy with conventional antibiotics. Result and Discussion: Imidazole derivatives disrupted biofilm integrity and enhanced antibiotic susceptibility in Pseudomonas aeruginosa and Staphylococcus aureus, with IC50 values ranging from 0.53 to 9.5 µM. Pyrazole-based compounds inhibited Staphylococcus epidermidis biofilms, with IC50 values ranging from 3.1 to 15.6 µg/mL. Indole derivatives, particularly pyrroloindoline triazole amides, inhibited MRSA biofilms with IC50 values as low as 2.8 µM by targeting quorum sensing and curli production. Quinoline compounds demonstrated greater than 90% inhibition of E. coli and P. aeruginosa biofilms and showed synergistic effects with antibiotics. Conclusion: Heterocyclic compounds exhibit promising antibiofilm activity, presenting a viable approach to overcoming AMR. These compounds not only disrupt biofilm formation but also enhance the efficacy of conventional antibiotics through synergistic interactions. Such synergy potentiates the antimicrobial effect by improving antibiotic penetration or disrupting resistance pathways. Future research should focus on optimizing pharmacokinetics and exploring these synergistic combinations to improve clinical applicability.

1 September 2023 in International Journal of Pharmaceutical Sciences Review and Research
Verified
Journal Article
Closed access
RMRajkumar Mondal
Rajkumar Mondal
TCTamalika Chakraborty
Tamalika Chakraborty
SGSutripto Ghosh
Sutripto Ghosh